Applied BioMath is proud to announce its most recent publication, An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates, published in the July 2015 edition of Pharmacuetical Research. Applied BioMath's John Burke PhD, Co-Founder, President, and CEO, and Joshua Apgar PhD, Co-Founder and CSO, in collaboration with scientists at ToxStrategies, Inc. co-authored the article which introduces key scientific and regulatory aspects of the nonclinical development of ADCs, discusses important regulatory and scientific issues in the nonclinical to clinical dose translation of ADCs, and introduces new concepts in the areas of pharmacokinetic/pharmacodynamic (PK/PD) modeling and simulation.
You are here
New Applied BioMath Publication: An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates
This publication, co-authored by John Burke PhD and Joshua Apgar PhD, appears in the July 2015 edition of Pharmaceutical Research
Thursday, July 9, 2015